Verified email-pattern data for Esocap Ag is currently limited. You can still use the company insights and contact sections below.
The Swiss-based, privately funded EsoCap AG pioneers the first and only system administering drugs for long-lasting local oesophageal therapy, meeting a major unmet medical need. Around 370 million people are affected by oesophageal diseases annually. The oesophagus is challenging as swallowed drugs pass through in seconds, impairing the effectiveness of local treatment.
The lead compound ESO-101 for treating eosinophilic oesophagitis (EoE) is ready to enter Phase IIb/III. ESO-101, a topical steroid for first-line EoE treatment, that has been shown to reduce inflammation due to prolonged, targeted 15-minute mucosal contact.
- The Technology -
EsoCap’s system centers on a capsule with coiled mucoadhesive film adhering to the oesophageal wall, releasing medication over time. MRI studies in healthy volunteers showed the film stays over 15 minutes, confirming effectiveness.
- ESO-101 phase IIb/III ready -
EsoCap successfully completed a double-blind, randomised, placebo-controlled Phase II study with ESO-101 in EoE, a chronic inflammatory disease, showing significant peak eosinophil reduction (p=0.0318).
- Market Potential -
The EoE market is forecast to reach USD 6.7bn in 2034 (USD 5bn in the US). ESO-101 is positioned as the only globally approved chronic first-line EoE treatment administered once daily with ESO-101’s user-friendly system.
- Future Applications -
EsoCap’s platform can deliver various drugs, including small molecules, biologics, and RNA. Future applications may target GERD, Barrett's oesophagus, and oesophageal cancer, addressing major unmet needs.
- Business Strategy -
ESO-101, designated an Orphan Drug by the FDA for EoE, is backed by robust patents in major markets including the U.S., Europe, Japan, Canada, and Mexico. With a skilled team and infrastructure, EsoCap plans to use Phase II data to partner with a leading biopharma company.
Company Details
- Employees
- 5
- Address
- Malzgasse, 9,switzerland
- Industry
- Biotechnology Research
- Website
- esocapbiotech.com
- Keywords
- biotech, drug delivery, upper gastrointestinal tract, eosinophilic esophagitis, treatment of diseases.
- HQ
- Basel, Basel-Town
Esocap Ag Questions
EsoCap AG's website is esocapbiotech.com
EsoCap AG's LinkedIn profile is https://ch.linkedin.com/company/esocap-biotech
EsoCap AG has
5 employees.
View email and phone details for 5
employees at EsoCap AG.
EsoCap AG's industry is
Biotechnology Research
EsoCap AG's top competitors are
Aurealis Therapeutics,
Cellestia Biotech,
Memo Therapeutics Ag,
Canvirex,
Cdr-Life Inc.,
Mosanna Therapeutics,
Novaremed Ag,
Nxi Therapeutics Ag,
Amyra Biotech Ag,
Idorsia Pharmaceuticals Ltd.
EsoCap AG's categories are Biotechnology Research
Explore related pages
Related company profiles:
Top EsoCap AG Employees
-
-
-
1hoffmann-partner.com -
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 10 free credits.
Search the #1 Contact Database
Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.